JY
ROIV icon

Jeff Yass’s Roivant Sciences ROIV Stock Holding History

Jeff Yass’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.2M Buy
513,900
+143,800
+39% +$4.25M ﹤0.01% 2576
2026
Q1 		$10.3M Sell
370,100
-993,700
-73% -$25.5M ﹤0.01% 3079
2025
Q4 		$29.6M Buy
1,363,800
+350,300
+35% +$6.91M ﹤0.01% 1836
2025
Q3 		$15.3M Buy
1,013,500
+725,700
+252% +$8.98M ﹤0.01% 2492
2025
Q2 		$3.24M Buy
287,800
+63,500
+28% +$688K ﹤0.01% 4814
2025
Q1 		$2.26M Sell
224,300
-49,700
-18% -$537K ﹤0.01% 5246
2024
Q4 		$3.24M Sell
274,000
-93,200
-25% -$1.1M ﹤0.01% 4331
2024
Q3 		$4.24M Sell
367,200
-153,200
-29% -$1.74M ﹤0.01% 3878
2024
Q2 		$5.5M Buy
520,400
+115,000
+28% +$1.26M ﹤0.01% 3297
2024
Q1 		$4.27M Sell
405,400
-891,100
-69% -$9.61M ﹤0.01% 3896
2023
Q4 		$14.6M Buy
1,296,500
+878,100
+210% +$8.56M ﹤0.01% 2154
2023
Q3 		$4.89M Buy
418,400
+137,700
+49% +$1.56M ﹤0.01% 3569
2023
Q2 		$2.83M Buy
280,700
+127,000
+83% +$1.14M ﹤0.01% 4469
2023
Q1 		$1.13M Buy
153,700
+12,400
+9% +$102K ﹤0.01% 6484
2022
Q4 		$1.13M Buy
+141,300
New +$786K ﹤0.01% 5899

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Jeff Yass's ROIV Position: Q2 2026 in Review

Jeff Yass increased its Roivant Sciences (ROIV) stake by 563% in Q2 2026, buying an estimated $32.6M and bringing the position to 1,301,013 shares worth $46M. The position accounts for ﹤0.01% of the portfolio, ranked #1594.

Jeff Yass first reported a position in ROIV in Q4 2021 and has held it in 18 quarters since. 496 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Jeff Yass held 1,301,013 shares of Roivant Sciences worth $46M as of Q2 2026.
  • Jeff Yass bought 1,104,818 Roivant Sciences shares in Q2 2026, an estimated $32.6M.
  • Roivant Sciences made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #1594 holding.
  • Jeff Yass first reported a position in Roivant Sciences in Q4 2021 and has held it in 18 quarters since.
  • 496 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.